Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma

Simple Summary Different Triazole Tetrac (TAT) thyrointegrin αvβ3 antagonists exhibited optimal therapeutic efficacy against U87 or primary glioblastoma cells. TAT containing molecules bind with high affinity to the integrin αvβ3 and plasma protein Transthyretin (TTR), which facilitate transport across the blood brain barrier. Biological studies showed that decreasing the PEG linker size (1600 versus 4000) or having mono-TAT versus bi-TAT had no significant impact on their αvβ3 binding affinity, anti-angiogenesis, and overall anti-cancer efficacy. Abstract Integrin αvβ3 receptors are overexpressed in different tumors and their associated neovascularization and hence, represent a potential cancer target. We previously synthesized a high affinity thyrointegrin αvβ3, P4000-bi-TAT (tetrac derivative), with potent anticancer properties. However, the long polydisperse PEG conjugate showed large scaleup and analytical/bioanalytical issues. Hence, in the present study, we synthesized a mono versus bi-triazole tetrac with discrete monodisperse PEG, which provided improvement in scaleup and bioanalysis. In the present study, we compared binding affinity and anticancer activates with a smaller PEG size (P1600-bi-TAT, Compound 2) and the removal of one TAT molecule (P1600-m-TAT, Compound 3) versus P4000-bi-TAT, Compound 1. The results of the selectivity and affinity of TATs showed greater affinity to integrin αvβ3. The xenograft weights and tumor cell viabilities were decreased by >90% at all doses compared to the control (ON Treatment, *** p < 0.001) in cells treated with Compounds 1, 2, and 3 in U87-Luc-treated mice. The in vivo luminescent signals of U87-luc cells reflect the proliferation and distribution of tumor cells in the animals and the maximum intensity corresponding to the maximum tumor cells that the animals could tolerate. We found that the three thyrointegrin αvβ3 antagonists exhibited optimal therapeutic efficacy against U87 or primary glioblastoma cells. Biological studies showed that decreasing the PEG linker size (1600 vs. 4000) or having mono-TAT or bi-TAT had no significant impact on their αvβ3 binding affinity, anti-angiogenesis, or overall anti-cancer efficacy.

[1]  S. Mousa,et al.  New Thyrointegrin αvβ3 Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme. , 2021, Journal of medicinal chemistry.

[2]  L. E. Ibarra,et al.  Understanding the glioblastoma tumor biology to optimize photodynamic therapy: From molecular to cellular events , 2020, Journal of neuroscience research.

[3]  S. Mousa,et al.  NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer , 2020, Cells.

[4]  S. Mousa,et al.  Nongenomic Actions of Thyroid Hormone: the Integrin Component. , 2020, Physiological reviews.

[5]  S. Mousa,et al.  Nanoformulated Bioactive Compounds Derived from Different Natural Products Combat Pancreatic Cancer Cell Proliferation , 2020, International journal of nanomedicine.

[6]  H. Cui,et al.  The Emerging Roles of RNA Modifications in Glioblastoma , 2020, Cancers.

[7]  S. Mousa,et al.  αvβ3 Integrin Antagonists Enhance Chemotherapy Response in an Orthotopic Pancreatic Cancer Model , 2020, Frontiers in Pharmacology.

[8]  Jun Yang,et al.  Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology , 2020, Theranostics.

[9]  S. Mousa,et al.  NDAT suppresses pro-inflammatory gene expression to enhance resveratrol-induced anti-proliferation in oral cancer cells. , 2019, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[10]  S. Mousa,et al.  Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin αvβ3 Antagonist with Potent Anticancer Activities in Glioblastoma Multiforme. , 2019, Bioconjugate chemistry.

[11]  S. Mousa,et al.  Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle , 2019, Scientific Reports.

[12]  M. Gauthier,et al.  Mechanisms of activity loss for a multi-PEGylated protein by experiment and simulation , 2019, Materials Today Chemistry.

[13]  S. Mousa,et al.  Evaluation of Angiogenesis Assays , 2019, Biomedicines.

[14]  M. Foley,et al.  Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations , 2019, bioRxiv.

[15]  Shubiao Zhang,et al.  RGD peptide-based non-viral gene delivery vectors targeting integrin αvβ3 for cancer therapy , 2019, Journal of drug targeting.

[16]  S. Mousa,et al.  Bioactivity of Thyroid Hormone Analogs at Cancer Cells , 2018, Front. Endocrinol..

[17]  Shaoyi Jiang,et al.  Zwitterlation mitigates protein bioactivity loss in vitro over PEGylation† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc01777h , 2018, Chemical science.

[18]  S. Mousa,et al.  Contributions of Thyroid Hormone to Cancer Metastasis , 2018, Biomedicines.

[19]  Benjamin Geiger,et al.  A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins , 2017, Scientific Reports.

[20]  S. Mousa,et al.  Actions of Thyroid Hormone Analogues on Chemokines , 2016, Journal of immunology research.

[21]  Zu-hua Gao,et al.  Arginine-Glycine-Aspartate–Binding Integrins as Therapeutic and Diagnostic Targets , 2016, American journal of therapeutics.

[22]  Atique U. Ahmed,et al.  The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence , 2015, Expert review of neurotherapeutics.

[23]  S. Prabhu,et al.  Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? , 2014, Drug discovery today.

[24]  S. Mousa,et al.  Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis , 2014, OncoTargets and therapy.

[25]  K. Aldape,et al.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[26]  Peng Zhan,et al.  Current drug research on PEGylation with small molecular agents , 2013 .

[27]  F. B. Davis,et al.  Molecular modeling of the thyroid hormone interactions with αvβ3 integrin , 2007, Steroids.

[28]  F. B. Davis,et al.  The Proangiogenic Action of Thyroid Hormone Analogue GC-1 Is Initiated at an Integrin , 2005, Journal of cardiovascular pharmacology.

[29]  Hung-Yun Lin,et al.  Proangiogenic Action of Thyroid Hormone Is Fibroblast Growth Factor–Dependent and Is Initiated at the Cell Surface , 2004, Circulation research.

[30]  G. Barnett,et al.  Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. , 2003, Anticancer research.

[31]  P. Hadváry,et al.  Conformational modulation of purified glycoprotein (GP) IIb-IIIa allows proteolytic generation of active fragments from either active or inactive GPIIb-IIIa. , 1992, The Journal of biological chemistry.